# Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

> **NCT00316953** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia
- Blastic Phase Chronic Myelogenous Leukemia
- Childhood Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Meningeal Chronic Myelogenous Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Relapsing Chronic Myelogenous Leukemia
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** dasatinib
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00316953
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2009-09
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2013-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316953, "Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00316953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*